Juvederm Volift — Vycross HA Filler for Mid-Deep Wrinkles & Perioral Region

Juvederm Volift is Allergan’s mid-range Vycross filler — 17.5 mg/mL cross-linked HA + 0.3% lidocaine combining low- and high-molecular-weight HA chains for efficient cross-linking. Engineered for mid-to-deep dermal placement targeting nasolabial folds, marionette lines, and the perioral region. Up to 15 months durability per Allergan clinical studies.

Juvederm Volift with Lidocaine is manufactured by Allergan / AbbVie, a France-based medical device and pharmaceutical company established in 1948. The product is part of the Juvederm dermal filler range, which is distributed across multiple international markets. Regulatory status: CE 0459 · Class III Medical Device · Manufactured in France.

Juvederm Volift with Lidocaine contains 17.5 mg/mL of cross-linked hyaluronic acid plus 0.3% (3 mg/mL) premixed lidocaine for injection comfort. The hyaluronic acid is non-animal, produced by bacterial fermentation and cross-linked using Allergan / AbbVie’s Patented Vycross Cross-Linking Technology technology. Phosphate-buffered saline at near-physiological pH carries the gel.

Per Allergan / AbbVie’s clinical data, Juvederm Volift with Lidocaine delivers Up to 15 months of correction depending on placement and patient factors. Duration depends on injection depth, dose, anatomical site, patient metabolism, and facial movement intensity. Mid to deep dermis placement typically delivers the longer end of the duration range.

Juvederm Volift with Lidocaine is engineered for mid to deep dermis placement. The standard recommended needle is 30G, supplied in the syringe blister pack. Some practitioners prefer a blunt-tip cannula of equivalent gauge for safer placement in highly vascular zones, particularly for deeper subcutaneous work.

Juvederm Volift with Lidocaine regulatory status: CE 0459 · Class III Medical Device · Manufactured in France. The product’s KFDA registration in South Korea is the primary regulatory baseline. CE marking and other international approvals enable distribution in the EU and other regulated markets. US FDA status varies — buyers in regulated jurisdictions should verify approval scope before importation and clinical use.

Store Juvederm Volift with Lidocaine between 2 °C and 25 °C in original packaging, away from direct sunlight. Do not freeze — freezing damages the HA gel structure. Shelf life is typically 24 months from the manufacturing date printed on the box when unopened. Once a syringe is opened, contents must be used immediately. Partial syringes cannot be retained for later use due to sterility risk.

No. Juvederm Volift with Lidocaine uses non-animal hyaluronic acid produced by bacterial fermentation — the standard manufacturing approach for modern HA dermal fillers. The product contains no animal proteins or by-products, making it suitable for patients who avoid animal-derived medical products. The product is contraindicated in patients with severe allergies to gram-positive bacterial proteins (used in HA fermentation).

Yes — layered protocols combining different fillers are standard aesthetic practice. Juvederm Volift with Lidocaine can be combined with other Korean or international HA fillers, neuromodulators (botulinum toxin), or biostimulators (PLLA, calcium hydroxylapatite) within a single session. Always wait the recommended interval between different injectable products and confirm biocompatibility per each manufacturer’s IFU.

Vycross is Allergan’s proprietary HA cross-linking technology that combines low-molecular-weight HA chains (for efficient cross-linking) with high-molecular-weight HA chains (for gel cohesivity). The result: a smooth, monophasic gel that integrates seamlessly into tissue with less swelling than older Hylacross formulations. In Volift specifically, Vycross enables a balance between lift capacity (sufficient for nasolabial folds) and spreadability (suitable for the perioral region’s dynamic movement) — making Volift versatile for combined mid-to-deep dermal protocols.